Merck: European Commission Approves TEPMETKO (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
TEPMETKO is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping,
Source: finanznachrichten.de